William Blair analyst Ryan Daniels has maintained their bullish stance on ALHC stock, giving a Buy rating on February 21.
Ryan Daniels has given his Buy rating due to a combination of factors that highlight Alignment Healthcare’s strong financial performance and promising outlook. The company reported impressive fourth-quarter results for 2024, with revenue significantly surpassing both guidance and consensus expectations. The adjusted EBITDA also performed well, landing in the upper half of the projected range, which indicates robust operational efficiency.
Looking ahead, the 2025 outlook appears favorable, bolstered by a remarkable annual enrollment period that saw a 35% increase in membership. This growth trajectory is expected to continue, with year-end membership guidance suggesting a 20% to 23% increase. Such growth is anticipated to drive substantial revenue gains, with projections exceeding consensus estimates. The company’s differentiated operating model positions it well to maintain strong performance in the competitive Medicare Advantage market, further justifying the Buy rating.
According to TipRanks, Daniels is a 4-star analyst with an average return of 7.2% and a 45.36% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Addus Homecare, HealthStream, and Evolent Health.
In another report released on February 21, Stifel Nicolaus also maintained a Buy rating on the stock with a $16.00 price target.